The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

Summary

The aim of prospective, open label, single center, randomized controlled trial is to investigate the efficacy of enavogliflozin on exercise performance, diastolic dysfunction, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF).

Timeline

Start

2024-05-01

Primary completion

2025-12-31

Completion

2026-06-30

Drugs

Indications